4//SEC Filing
Lehrer-Graiwer Joshua 4
Accession 0000899243-21-027011
CIK 0001815776other
Filed
Jun 30, 8:00 PM ET
Accepted
Jul 1, 7:00 PM ET
Size
22.5 KB
Accession
0000899243-21-027011
Insider Transaction Report
Form 4
Lehrer-Graiwer Joshua
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2021-01-16−374,013→ 0 totalExercise: $0.30Exp: 2031-01-12→ Common Stock (374,013 underlying) - Award
Stock Option (right to buy)
2021-03-17+795,196→ 795,196 totalExercise: $6.11Exp: 2031-03-16→ Common Stock (795,196 underlying) - Award
Stock Option (right to buy)
2021-01-13+374,013→ 374,013 totalExercise: $0.30Exp: 2031-01-12→ Common Stock (374,013 underlying) - Award
Series B Preferred Stock
2021-03-11$5.06/sh+19,763$100,001→ 19,763 total→ Common Stock (8,126 underlying) - Award
Stock Option (right to buy)
2021-03-17+340,798→ 340,798 totalExercise: $6.11Exp: 2031-03-16→ Common Stock (340,798 underlying) - Conversion
Series B Preferred Stock
2021-06-29−19,763→ 0 total→ Common Stock (8,126 underlying) - Exercise/Conversion
Common Stock
2021-01-16$0.30/sh+374,013$112,204→ 1,153,544 total - Conversion
Common Stock
2021-06-29+8,126→ 1,161,670 total
Footnotes (6)
- [F1]This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.
- [F2]On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split.
- [F3]These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date.
- [F4]25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after April 20, 2020, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. The option provides for an early exercise provision of unvested shares, subject to the Issuer's right to repurchase.
- [F5]1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
- [F6]The option was granted subject to the achievement by the Company of performance vesting criteria. On June 29, 2021 the performance vesting criteria was met such that the option became reportable. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.
Documents
Issuer
Graphite Bio, Inc.
CIK 0001815776
Entity typeother
Related Parties
1- filerCIK 0001789673
Filing Metadata
- Form type
- 4
- Filed
- Jun 30, 8:00 PM ET
- Accepted
- Jul 1, 7:00 PM ET
- Size
- 22.5 KB